Altay Therapeutics is a biotechnology company developing small-molecule inhibitors of transcription factors, using a discovery platform that targets allosteric binding pockets on targets long considered undruggable, with AI modeling and in silico docking to identify antagonists. Its lead candidate DX5057 is an oral small molecule designed to block DUX4, positioned as the first oral DUX4 inhibitor in development for facioscapulohumeral muscular dystrophy (FSHD), a disease with no approved disease-modifying therapies; the pipeline also includes a STAT3 inhibitor and an ETS-family inhibitor with potential across several cancers. Founded by Chief Scientific Officer Ali Ozes and led by CEO James Breitmeyer, the company is Y Combinator-backed and was seeded by the non-profit SOLVE FSHD before closing its $37 million Series A.
1
Round
1
Industry
4
Tags
Oct 14, 2026
Latest raise
Funding activity · 1 round
Oct 14, 2026
$37M
Series A
Led by Sound Bioventures
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
